EMA Issues Advice on Lilly's Etesevimab (LY-CoV016) Developed by IMCAS and Junshi Biosciences together with Bamlanivimab (LY-CoV555) for the treatment of COVID-19 in EU

Text Size: A   A   A

On March 5, 2021, PR Newswire reported that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) supported European Union (EU) member states to use monoclonal antibodies (LY-CoV555) and (LY-CoV016, also known as JS016) in public health emergencies for the treatment of confirmed COVID-19 in the European Union. Etesevimab (LY-CoV016) was jointly developed by the Institute of Microbiology, Chinese Academy of Science (IMCAS) and Junshi Biosciences.


CHMP has completed a review of available data for both antibodies for the treatment of confirmed COVID-19, and recommended that for patients aged 12 years and above, who do not require supplementary oxygen, and are at high risk of progressing to more severe COVID-19, use LY- Combination therapy of CoV555 and LY-CoV016.


On February 9, 2021, the U.S. Food and Drug Administration (FDA) has approved the emergency use of the therapy in the United States for the treatment of patients with mild and moderate COVID-19 infections.


The picture shows the etesevimab and bamlanivimab, the red is LY-CoV016 jointly developed by IMCAS and Junshi Biosciences and the black is LY-CoV555